In a kind of malignant lymphoma of the op Zeb consolidated close to approval, found about price cuts have been studied near the effectiveness of approval
[ad_1]
,
high therapeutic effect can be expected on the other hand, higher prices and new types of anti-cancer drugs, "opzi-Bo", Ministry of health, labor and welfare is new to a kind of malignant lymphoma of the effectiveness of policies.
Enhance the immune system of the body
11, the Ministry of health experts, new malignant lymphoma, Hodgkin's lymphoma cancer patients who are effectiveness are acceptable and should be approved. Consolidated policy to approve close patients number of illnesses in the country approximately 2000 people and the Ministry of health received a report of this, an estimated op Zeb remedy for illness as well.
And as more patients is estimated to cost approximately 35 million yen and over
opzi-Bo lung cancer cases, 60 kg male patients for one year to use your to squeeze the nation's finances are concerned. For this reason, consider limiting use to patients with a significant reduction in the price or the effects can be expected, such as.
JAPANESE
高い治療効果が期待できる一方で、価格が高く、薬価の引き下げが検討されている新しいタイプの抗がん剤、「オプジーボ」について、厚生労働省は、新たに悪性リンパ腫の一種にも有効性が認められるとして、近く承認する方針を固めました。